Aridis Pharmaceuticals LLC's Also see "Aridis Pharmaceuticals LLC " - Scrip, 1 May, 2008. lead preclinical candidate is Panaecin, which is a reformulation of a commercial product containing gallium that is used to treat hypercalcemia in cancer patients. Since gallium also has anti-infective properties, Aridis plans to develop it as an inhaled powder, initially targeting cystic fibrosis patients.
BioMarck Pharmaceuticals Ltd. Also see "BioMarck Pharmaceuticals Ltd. " - Scrip, 1 May, 2008. is developing an inhaled...